266 related articles for article (PubMed ID: 29179865)
1. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
3. Social mobilisation, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries.
Kabakama S; Gallagher KE; Howard N; Mounier-Jack S; Burchett HE; Griffiths UK; Feletto M; LaMontagne DS; Watson-Jones D
BMC Public Health; 2016 Aug; 16(1):834. PubMed ID: 27543037
[TBL] [Abstract][Full Text] [Related]
4. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
5. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
6. The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries.
Howard N; Mounier-Jack S; Gallagher KE; Kabakama S; Griffiths UK; Feletto M; LaMontagne DS; Burchett HE; Watson-Jones D
Hum Vaccin Immunother; 2016 Sep; 12(9):2475-7. PubMed ID: 27159786
[TBL] [Abstract][Full Text] [Related]
7. Human papilloma virus vaccine for low and middle income countries: A step too soon?
Jindal HA; Kaur A; Murugan S
Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
[TBL] [Abstract][Full Text] [Related]
8. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
9. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.
Wigle J; Coast E; Watson-Jones D
Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
12. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Griffiths UK; Feletto M; Burchett HED; LaMontagne DS; Watson-Jones D
PLoS One; 2017; 12(6):e0177773. PubMed ID: 28575074
[TBL] [Abstract][Full Text] [Related]
13. Progress in HPV vaccination in low- and lower-middle-income countries.
LaMontagne DS; Bloem PJN; Brotherton JML; Gallagher KE; Badiane O; Ndiaye C
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():7-14. PubMed ID: 28691329
[TBL] [Abstract][Full Text] [Related]
14. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.
Silas OA; Achenbach CJ; Murphy RL; Hou L; Sagay SA; Banwat E; Adoga AA; Musa J; French DD
Expert Rev Vaccines; 2018 Jan; 17(1):91-98. PubMed ID: 29183182
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
17. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates.
Jeudin P; Liveright E; Del Carmen MG; Perkins RB
Clin Ther; 2014 Jan; 36(1):24-37. PubMed ID: 24417783
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
19. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
20. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts.
Jit M; Levin C; Brisson M; Levin A; Resch S; Berkhof J; Kim J; Hutubessy R
BMC Med; 2013 Jan; 11():23. PubMed ID: 23363734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
